{"database": "lobbying", "table": "lobbying_activities", "rows": [[3004477, "5ec12dbc-ae37-460b-86d6-5ce5efaba815", "Q2", "MARSHALL & POPP, LLC", 401105121, "GENENTECH, INC.", 2023, "second_quarter", "PHA", "Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, and H.R. 2679, the PBM Accountability Act,. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2023-07-14T16:05:24-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["3004477"], "units": {}, "query_ms": 3.756112069822848, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}